{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T11:37:00Z","timestamp":1743075420419,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":40,"publisher":"Springer New York","isbn-type":[{"type":"print","value":"9781493939978"},{"type":"electronic","value":"9781493939992"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/978-1-4939-3999-2_13","type":"book-chapter","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T06:09:54Z","timestamp":1479362994000},"page":"139-149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Orthotopic Model of Ovarian Cancer"],"prefix":"10.1007","author":[{"given":"Alessandra","family":"Decio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Giavazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,18]]},"reference":[{"issue":"1","key":"13_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5\u201329","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"13_CR2","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","volume":"21","author":"GC Stuart","year":"2011","unstructured":"Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J et al (2011) 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21(4):750\u2013755","journal-title":"Int J Gynecol Cancer"},{"issue":"9951","key":"13_CR3","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014) Ovarian cancer. Lancet 384(9951):1376\u20131388","journal-title":"Lancet"},{"issue":"2","key":"13_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ygyno.2013.11.029","volume":"132","author":"RN Eskander","year":"2014","unstructured":"Eskander RN, Tewari KS (2014) Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma\u2014mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol 132(2):496\u2013505","journal-title":"Gynecol Oncol"},{"key":"13_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fonc.2014.00026","volume":"4","author":"CD House","year":"2014","unstructured":"House CD, Hernandez L, Annunziata CM (2014) Recent technological advances in using mouse models to study ovarian cancer. Front Oncol 4:26. doi:\n                  10.3389\/fonc.2014.00026","journal-title":"Front Oncol"},{"key":"13_CR6","doi-asserted-by":"crossref","unstructured":"Kuhn E, Tisato V, Rimondi E, Secchiero P (2015) Current preclinical models of ovarian cancer. J Carcinog Mutagen 6(2). doi:10.4172\/2157-2518.1000220","DOI":"10.4172\/2157-2518.1000220"},{"issue":"28","key":"13_CR7","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1038\/onc.2013.321","volume":"33","author":"E Lengyel","year":"2014","unstructured":"Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P et al (2014) Epithelial ovarian cancer experimental models. Oncogene 33(28):3619\u20133633","journal-title":"Oncogene"},{"issue":"23","key":"13_CR8","doi-asserted-by":"publisher","first-page":"6980","DOI":"10.1158\/0008-5472.CAN-14-0274","volume":"74","author":"F Ricci","year":"2014","unstructured":"Ricci F, Bizzaro F, Cesca M, Guffanti F, Ganzinelli M, Decio A et al (2014) Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res 74(23):6980\u20136990","journal-title":"Cancer Res"},{"issue":"5","key":"13_CR9","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1158\/1078-0432.CCR-13-2611","volume":"20","author":"SJ Weroha","year":"2014","unstructured":"Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ et al (2014) Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res 20(5):1288\u20131297","journal-title":"Clin Cancer Res"},{"key":"13_CR10","doi-asserted-by":"publisher","first-page":"14495","DOI":"10.1038\/srep14495","volume":"5","author":"NG Alkema","year":"2015","unstructured":"Alkema NG, Tomar T, Duiker EW, Jan Meersma G, Klip H, van der Zee AG et al (2015) Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods. Sci Rep 5:14495","journal-title":"Sci Rep"},{"issue":"29","key":"13_CR11","doi-asserted-by":"publisher","first-page":"28327","DOI":"10.18632\/oncotarget.5069","volume":"6","author":"PE Colombo","year":"2015","unstructured":"Colombo PE, du Manoir S, Orsett B, Bras-Goncalves R, Lambros MB, MacKay A et al (2015) Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure. Oncotarget 6(29):28327\u201328340","journal-title":"Oncotarget"},{"issue":"6","key":"13_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","volume":"9","author":"JJ Tentler","year":"2012","unstructured":"Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM et al (2012) Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9(6):338\u2013350","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"13_CR13","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2174\/138945012803530152","volume":"13","author":"SP Langdon","year":"2012","unstructured":"Langdon SP (2012) Animal modeling of cancer pathology and studying tumor response to therapy. Curr Drug Targets 13(12):1535\u20131547","journal-title":"Curr Drug Targets"},{"issue":"6","key":"13_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.ejca.2004.01.003","volume":"40","author":"JK Peterson","year":"2004","unstructured":"Peterson JK, Houghton PJ (2004) Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 40(6):837\u2013844","journal-title":"Eur J Cancer"},{"issue":"8","key":"13_CR15","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1158\/0008-5472.CAN-08-4210","volume":"69","author":"VC Daniel","year":"2009","unstructured":"Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM et al (2009) A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 69(8):3364\u20133373","journal-title":"Cancer Res"},{"issue":"6","key":"13_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ctrv.2013.01.005","volume":"39","author":"F Ricci","year":"2013","unstructured":"Ricci F, Broggini M, Damia G (2013) Revisiting ovarian cancer preclinical models: implications for a better management of the disease. Cancer Treat Rev 39(6):561\u2013568","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"13_CR17","first-page":"14","volume":"4","author":"N Hasan","year":"2015","unstructured":"Hasan N, Ohman AW, Dinulescu DM (2015) The promise and challenge of ovarian cancer models. Transl Cancer Res 4(1):14\u201328","journal-title":"Transl Cancer Res"},{"issue":"2","key":"13_CR18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/bjc.2012.261","volume":"107","author":"P Oliva","year":"2012","unstructured":"Oliva P, Decio A, Castiglioni V, Bassi A, Pesenti E, Cesca M et al (2012) Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. Br J Cancer 107(2):360\u2013369","journal-title":"Br J Cancer"},{"issue":"3","key":"13_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","volume":"34","author":"RJ Kurman","year":"2010","unstructured":"Kurman RJ, Shih Ie M (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34(3):433\u2013443","journal-title":"Am J Surg Pathol"},{"key":"13_CR20","doi-asserted-by":"crossref","unstructured":"Nunez-Cruz S, Connolly DC, Scholler N (2010) An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses. J Vis Exp (45). doi:2146 [pii] 10.3791\/2146","DOI":"10.3791\/2146"},{"issue":"2","key":"13_CR21","first-page":"283","volume":"13","author":"X Fu","year":"1993","unstructured":"Fu X, Hoffman RM (1993) Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res 13(2):283\u2013286","journal-title":"Anticancer Res"},{"issue":"6","key":"13_CR22","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ymthe.2004.08.013","volume":"10","author":"TJ Shaw","year":"2004","unstructured":"Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC (2004) Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 10(6):1032\u20131042","journal-title":"Mol Ther"},{"issue":"1","key":"13_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejca.2003.08.008","volume":"40","author":"Y Tamada","year":"2004","unstructured":"Tamada Y, Aoki D, Nozawa S, Irimura T (2004) Model for paraaortic lymph node metastasis produced by orthotopic implantation of ovarian carcinoma cells in athymic nude mice. Eur J Cancer 40(1):158\u2013163","journal-title":"Eur J Cancer"},{"issue":"4","key":"13_CR24","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ajpath.2013.12.030","volume":"184","author":"A Decio","year":"2014","unstructured":"Decio A, Taraboletti G, Patton V, Alzani R, Perego P, Fruscio R et al (2014) Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. Am J Pathol 184(4):1050\u20131061","journal-title":"Am J Pathol"},{"issue":"2","key":"13_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ygyno.2007.10.035","volume":"108","author":"J Greenaway","year":"2008","unstructured":"Greenaway J, Moorehead R, Shaw P, Petrik J (2008) Epithelial\u2013stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. Gynecol Oncol 108(2):385\u2013394","journal-title":"Gynecol Oncol"},{"issue":"7","key":"13_CR26","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10585-015-9734-1","volume":"32","author":"A Decio","year":"2015","unstructured":"Decio A, Cesca M, Bizzaro F, Porcu L, Bettolini R, Ubezio P et al (2015) Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin. Clin Exp Metastasis 32(7):647\u2013658","journal-title":"Clin Exp Metastasis"},{"key":"13_CR27","doi-asserted-by":"crossref","unstructured":"Cesca M, Morosi L, Berndt A, Fuso Nerini I, Frapolli R, Richter P et al (2016) Bevacizumab-induced inhibition of angiogenesis promotes a more homogeneous intratumoral distribution of paclitaxel, improving the antitumor response. Mol Cancer Ther. 15(1):125\u201335","DOI":"10.1158\/1535-7163.MCT-15-0063"},{"issue":"9","key":"13_CR28","doi-asserted-by":"publisher","first-page":"e24420","DOI":"10.1371\/journal.pone.0024420","volume":"6","author":"RB Bankert","year":"2011","unstructured":"Bankert RB, Balu-Iyer SV, Odunsi K, Shultz LD, Kelleher RJ Jr, Barnas JL et al (2011) Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS One 6(9):e24420","journal-title":"PLoS One"},{"issue":"11","key":"13_CR29","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","volume":"102","author":"P Workman","year":"2010","unstructured":"Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ et al (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102(11):1555\u20131577","journal-title":"Br J Cancer"},{"issue":"11","key":"13_CR30","first-page":"3549","volume":"5","author":"M Yang","year":"1999","unstructured":"Yang M, Jiang P, An Z, Baranov E, Li L, Hasegawa S et al (1999) Genetically fluorescent melanoma bone and organ metastasis models. Clin Cancer Res 5(11):3549\u20133559","journal-title":"Clin Cancer Res"},{"issue":"7\u20138","key":"13_CR31","first-page":"315","volume":"23","author":"Y Amoh","year":"2006","unstructured":"Amoh Y, Bouvet M, Li L, Tsuji K, Moossa AR, Katsuoka K et al (2006) Visualization of nascent tumor angiogenesis in lung and liver metastasis by differential dual-color fluorescence imaging in nestin-linked-GFP mice. Clin Exp Metastasis 23(7\u20138):315\u2013322","journal-title":"Clin Exp Metastasis"},{"issue":"12","key":"13_CR32","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/nbt1037","volume":"22","author":"NC Shaner","year":"2004","unstructured":"Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, Tsien RY (2004) Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 22(12):1567\u20131572","journal-title":"Nat Biotechnol"},{"issue":"9","key":"13_CR33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nmeth1083","volume":"4","author":"D Shcherbo","year":"2007","unstructured":"Shcherbo D, Merzlyak EM, Chepurnykh TV, Fradkov AF, Ermakova GV, Solovieva EA et al (2007) Bright far-red fluorescent protein for whole-body imaging. Nat Methods 4(9):741\u2013746","journal-title":"Nat Methods"},{"issue":"5928","key":"13_CR34","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1126\/science.1168683","volume":"324","author":"X Shu","year":"2009","unstructured":"Shu X, Royant A, Lin MZ, Aguilera TA, Lev-Ram V, Steinbach PA et al (2009) Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome. Science 324(5928):804\u2013807","journal-title":"Science"},{"key":"13_CR35","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1146\/annurev.bi.58.070189.004405","volume":"58","author":"A Landy","year":"1989","unstructured":"Landy A (1989) Dynamic, structural, and regulatory aspects of lambda site-specific recombination. Annu Rev Biochem 58:913\u2013949","journal-title":"Annu Rev Biochem"},{"key":"13_CR36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1471-2407-9-106","volume":"9","author":"CS Snyder","year":"2009","unstructured":"Snyder CS, Kaushal S, Kono Y, Tran Cao HS, Hoffman RM, Bouvet M (2009) Complementarity of ultrasound and fluorescence imaging in an orthotopic mouse model of pancreatic cancer. BMC Cancer 9:106","journal-title":"BMC Cancer"},{"key":"13_CR37","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/978-1-62703-287-2_13","volume":"980","author":"SA Sastra","year":"2013","unstructured":"Sastra SA, Olive KP (2013) Quantification of murine pancreatic tumors by high-resolution ultrasound. Methods Mol Biol 980:249\u2013266","journal-title":"Methods Mol Biol"},{"issue":"11","key":"13_CR38","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.4161\/cbt.6.11.4830","volume":"6","author":"H Hensley","year":"2007","unstructured":"Hensley H, Quinn BA, Wolf RL, Litwin SL, Mabuchi S, Williams SJ et al (2007) Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biol Ther 6(11):1717\u20131725","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"13_CR39","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7150\/thno.7996","volume":"4","author":"M Gerling","year":"2014","unstructured":"Gerling M, Zhao Y, Nania S, Norberg KJ, Verbeke CS, Englert B et al (2014) Real-time assessment of tissue hypoxia in vivo with combined photoacoustics and high-frequency ultrasound. Theranostics 4(6):604\u2013613","journal-title":"Theranostics"},{"key":"13_CR40","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1038\/srep05329","volume":"4","author":"RJ Paproski","year":"2014","unstructured":"Paproski RJ, Heinmiller A, Wachowicz K, Zemp RJ (2014) Multi-wavelength photoacoustic imaging of inducible tyrosinase reporter gene expression in xenograft tumors. Sci Rep 4:5329","journal-title":"Sci Rep"}],"container-title":["Methods in Molecular Biology","Tumor Angiogenesis Assays"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-3999-2_13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:03:18Z","timestamp":1558051398000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-3999-2_13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9781493939978","9781493939992"],"references-count":40,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-3999-2_13","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"18 November 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}